Vitiligo in Children: Whatâ€™s New in Treatment? by Gianfaldoni, Serena et al.
 
Open Access Maced J Med Sci electronic publication ahead of print,  
published on January 21, 2018 as https://doi.org/10.3889/oamjms.2018.060 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                          1 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 
Special Issue: Global Dermatology-2 
https://doi.org/10.3889/oamjms.2018.060 
eISSN: 1857-9655 
Review Article 
 
 
  
 
Vitiligo in Children: What’s New in Treatment? 
 
 
Serena Gianfaldoni
1*
, Georgi Tchernev
2,3
, Uwe Wollina
4
, Jacopo Lotti
5
, Miriam Rovesti
6
, Francesca Satolli
6
, Katlein França
7
, 
Torello Lotti
1 
 
1
University G. Marconi of Rome, Dermatology and Venereology, Rome, Italy; 
2
Medical Institute of Ministry of Interior 
Department of General, Vascular and Abdominal Surgery, Sofia, Bulgaria; 
3
Onkoderma - Policlinic for Dermatology and 
Dermatologic Surgery, Sofia, Bulgaria; 
4
Städtisches Klinikum Dresden, Department of Dermatology and Venereology, 
Dresden, Sachsen, Germany; 
5
University G. Marconi of Rome - Dept. of Nuclear, Subnuclear and Radiation Physics, Rome, 
Italy; 
6
Department of Dermatology, University of Parma, Parma, Italy;
 7
University of Miami School of Medicine, Miami, 
Florida, United States and Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi”, 
Rome, Italy 
 
Citation: Gianfaldoni S, Tchernev G, Wollina U, Lotti J, 
Rovesti M, Satolli F, França K, Lotti T. Vitiligo in Children: 
What’s New in Treatment? Open Access Maced J Med 
Sci. https://doi.org/10.3889/oamjms.2018.060 
Keywords: Childhood vitiligo; Innovative treatments; 
Excimer laser; Micro-focused phototherapy; UVA-1 laser; 
selective sunlight therapy; Immunomodulatory agent; 
Antioxidants; Low dose medicine; Dead Sea 
Climatotherapy 
*Correspondence: Serena Gianfaldoni. University G. 
Marconi of Rome - Dermatology and Venereology, 
University G. Marconi of Rome, Rome, Italy. E-mail: 
serena.gianfaldoni@gmail.com 
Received: 14-Sep-2017; Revised: 25-Dec-2017; 
Accepted: 26-Dec-2017; Online first: 21-Jan-2018 
Copyright: © 2018 Serena Gianfaldoni, Georgi Tchernev, 
Uwe Wollina, Jacopo Lotti, Miriam Rovesti, Francesca 
Satolli, Katlein França, Torello Lotti. This is an open-
access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial 4.0 International 
License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
Abstract  
Vitiligo is an acquired chronic hypopigmentary disorder, which usually stars in childhood. The Authors discuss a 
short review of the more innovative therapies for childhood vitiligo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Vitiligo is an acquired chronic hypopigmentary 
disorder, which usually stars in childhood. Even if 
today different kind of therapies, both medical and 
surgical, are available [1] (Table 1), none of them may 
be considered as a standard gold treatment for the 
variable results in term of repigmentation and the risk 
of side effects. 
Fortunately, innovative treatments have been 
introducing to solve this problem. They consist in 
either innovation of conventional treatments and real 
new therapies. 
 
 
Innovative phototherapeutic treatments 
 
Among the conventional treatments for 
childhood vitiligo, phototherapies may be represent 
the most effective therapies, especially for generalised 
vitiligo [2]. 
Table 1: Current therapeutic options for vitiligo in children 
Calcineurin inhibitors Immunomodulation Burning sensation, erythema, transient 
pruritus; risk of malignancies? 
Calcipotriol Repigmentation, immunosuppression Transient burning or irritation 
Corticosteroids Immunomodulation Epidermal atrophy, striae, telangiectasia, 
glaucoma, tachyphylaxis, hypothalamus-
pituitary axis suppression, Cushing's 
syndrome, growth retardation 
Corticosteroids Immunomodulation Glaucoma, tachyphylaxis, hypothalamus-
pituitary axis suppression, Cushing's 
syndrome, growth retardation 
PUVA (12yo), Topical 
PUVA, Topical PUVA sol, 
nbUVB 
Repigmentation, immunomodulation Erythema, itching or burning sensation; 
chronic actinic damage; psoralen 
toxicity (nausea, vomiting, abdominal 
pain, liver toxicity, 
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In the last decade's new techniques, both 
natural and artificial, are being introduced to achieve 
better clinical results in term of repigmentation, with 
fewer side effects (Table 2). 
Table 2: Innovative modalities of phototherapy 
The Dead Sea 
Selective sunlight therapy 
Excimer laser/ Monochromatic excimer light (MEL) 
Focused microphototherapy 
LASER ALBA UVA1 355nm 
 
 
 
Natural exposure to the sunlight at the 
Dead Sea (“Dead Sea Climatotherapy”) 
 
It is now clear how at the Dead Sea, the 
sunlight travels below the normal sea level, 
attenuating the low range of UVB spectrum, which is 
the non - therapeutic ones. This fact explains how 
vitiliginous patients show a greater improvement in 
skin lesions after sunlight therapy in this special 
geographical area [3]. The therapeutical protocol 
varies by the characteristics of patients (e.g. skin 
phototype, age, comorbidities) and of their skin 
disease. In general, it consists of the daily session, 
with a gradual increase of the exposure time. 
Many data support the efficacy of Dead Sea 
Climatotherapy (DSC) in inducing repigmentation and, 
not less important, in improving the quality of life of 
patients [4]. 
Interestingly, a study shows the opportunity to 
combine DSC with the topical application of a 
pseudocatalase cream, for achieving a faster 
repigmentation [5]. Pseudocatalase, however, is a 
controversial issue. One open trial from London, UK 
[6] and two randomised, double-blind trials – one from 
Iran and another one from Australia – could not 
demonstrate any beneficial effect of this compound 
compared to placebo [7][8]. 
  
 
Selective sunlight phototherapy 
 
Another innovation is the selective sunlight 
phototherapy. Recently, a topical cream 
(PHOTOCIL®) has been introduced to selectively 
deliver nb - UVB therapy, when exposed to solar 
ultraviolet irradiation. The cream is composed by 
diethylamino hydroxy benzoyl hexyl benzoate and by 
alpha - glucosyl hesperidin, a glucosylated derivative 
of a natural plant flavonoid, formulated into a water 
and oil emulsion. It is applied on vitiliginous patches, 
while a broadband SPF 50 sunscreen is applied on 
the unaffected skin. The treatment seems to be 
effective and safe, providing good results in term of 
regimentation [9][10]. 
 
 
Excimer lasers 
 
Among the artificial radiation therapies, 
excimer lasers are probably the oldest phototherapy 
to have been introduced for vitiligo treatment. They 
consist of xenon chloride lasers, delivering radiation of 
308 nm, with a variable spot size (mean value: 15 - 25 
mm). The therapeutic protocol varies on the bases of 
characteristics of patient, disease and delivery 
system. The therapeutic procedure schedules consist 
of two sessions in a week for 13 weeks. During the 
first session, the operator estimates the MED (Minimal 
Erythema Dose) of the patient in a vitiliginous area, to 
be able to set the first dose of radiation, 
corresponding to the MED decreased by 10%. During 
the following sessions, the dose increases gradually 
depending on the clinical response [11]. 
Excimer lasers are proved to be effective for 
the treatment of localised forms of vitiligo. The rate 
and speed of repigmentation vary accordingly with the 
site and duration of the disease. Lesions on the face 
and neck are highly respondent areas, while 
extremities show a slower response [12]. 
The treatment is quite safe. A part of a 
supposed chronic skin photo - damages, the more 
common side effects is represented by perilesional 
hyperpigmentation, burns, and folliculitis. 
An excimer laser may be used alone or in 
association with topical therapies (e.g. tacrolimus, 
tacalcitol), which seems to provide better results in 
term of repigmentation [13]. 
 
 
Narrow - band UVB target phototherapy 
and narrow - band UVB micro-focused 
phototherapy  
 
More innovative is the target phototherapy 
which allows the operator to treat only the 
hypopigmented areas, sparing the uninvolved skin. 
While the mechanisms of action are the same 
of the classical phototherapy, the target phototherapy 
acts in a more precise way because, treating only 
vitiliginous patches, the operator can use a more 
appropriate dose of energy, leading to shorter 
duration and less frequent treatment sessions [14]. In 
the last years, many different target phototherapy 
devices have been introduced in the clinical practice. 
Among these, the last frontier of vitiligo therapy is 
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represented by the BIOSKIN EVOLUTION® device, a 
cold light generator micro-focused phototherapy 
(Table 3). 
Table 3: Conventional phototherapy versus micro-focused 
phototherapy 
Exposure to affected and unaffected skin 
areas 
Treatment focused on skin lesions 
Difficulty in treating certain skin areas (e.g. 
ear, nose) 
Possibility to treat difficult areas thanks to a 
manoeuvrable hand piece 
Slow delivery system, which needs longer 
treatment sessions 
Quick delivery system. Treating only 
skin lesions, operators can also use higher 
doses of energy, achieving faster response 
on selected areas 
Multiple and frequent visits to clinic Shorten and less frequent visits 
Bulky machines Smaller device 
Difficulty in treating claustrophobic patients 
and children, who may be afraid of the large 
device 
Easy administration of the energy 
delivery and well tolerate - therapy 
 
 It consists of a short arc lamp generating a 
beam of visible, ultraviolet radiations, filtered to obtain 
only nb - UVB. BIOSKIN EVOLUTION® can provide a 
spectrum of intensity up to 400 mW/cm² and the peak 
of emission at 311 nm. The possibility to treat only 
vitiliginous patches, allows the operator to obtain 
lesional repigmentation, without an increase in the 
colour contrast between affected and not affected skin 
areas.  
The therapeutic protocol (energy level, spot 
light, no. of the session, duration) is decided by the 
operator by patients’ characteristics. The therapy is 
repeated once every three weeks, with the possibility 
to effect 2 sessions in the same day, for a total of 6 
months.  
Many data suggest how nb - UVB micro-
focused phototherapy should be considered as first-
choice therapy for localized vitiligo, where it may 
provide good clinical results in term of restoring 
pigmentation, patients’ compliance, and safety 
[15][16]. 
 
 
UVA - 1 therapy 
 
Recently, light therapy lamps with halogen-
metal band confined to the high irradiance UVA1 (340 
- 400 nm) have experienced a growing interest and 
used in dermatology. The well-documented immune- 
modulating effects of UVA - 1, make this type of 
phototherapy useful for the treatment of several skin 
diseases, such as atopic dermatitis, psoriasis, vitiligo 
and other [17]. 
The therapeutic procedure schedules for 
vitiligo, usually, consists in 3 - 5 sessions per week, 
with a starting dose of 20 - 30 J/cm
2
, which is 
progressively increased in the following sessions to 
the full dose. The treatment is well tolerated. The most 
common side effects are tanning, erythema, pruritus 
and phototoxic reactions (eczema, urticaria). The 
long-term side effects are yet to be investigated [18]. 
UVA - 1 target laser 
 
Laser Alba 355® is an innovative, focused 
laser technology based on UVA - 1 spectrum with a 
wavelength of 355 nm (Table 4).  
Table 4: Clinical indication for Laser Alba 355® 
CLINICAL INDICATIONS 
Atopic dermatitis 
Dyshidrotic dermatitis 
Psoriasis 
Pityriasis rosea 
Prurigo 
Urticaria pigmentosa/Mastocytosis 
Localized scleroderma (morphea) 
Systemic lupus erythematosus 
Lichen sclerosis 
Mycosis fungoides and another T-cell lymphoma 
Others: Vitiligo, Graft versus host disease, Granuloma annulare, Necrobiosis lipoidica, 
Cutaneous sarcoidosis, Follicular mucinosis, POEMS syndrome, Scleromyxedema, 
Hypereosinophilic syndrome, Pityriasis lichenoides 
 
It consists of an active medium and a 
Neodymium - doped yttrium orthovanadate (Nd: 
YVO4) crystal that is “energetically pumped” by 
another laser with 808 nm wavelength. The light 
emitted by the Nd: YVO4, at a wavelength equal to 
1064 nm, is impulsed through an acoustic-optic crystal 
named Q - switch, producing a frequency of 20 - 50 
kHz and transforming the laser light into an ultrashort 
pulsed light (25 nano sec). This pulse rate is higher 
than 40 kW, and it is sent to crystals to duplicate and 
triplicate the 1064 nm wavelength. Thus it produces a 
second (532 nm) and third (355 nm) harmonic 
wavelength delivery. The laser beam is then filtered 
by a harmonic separating mirror to select from this 
galvanometric head a 355 nm wavelength specific 
beam which is amplified and homogenate, before 
galvanometric head output, with a 2.5 mm spot and a 
pulse repeating potential up to 20.000 spots/second 
and designing variously shaped dimensional figures 
[19]. 
The use of Laser Alba 355® allows the 
treatment of selected affected skin areas so that the 
operator can use a more appropriate dose of energy, 
leading to shorter duration and less frequent treatment 
sessions. Time of emission and spot diameters are 
regulated by the operator, on the base of the clinical 
characteristic of individual patients. The treatment with 
Laser Alba 355® is well - tolerated. Acute side effects, 
such as erythema or pruritus, have rarely been 
described. Long-term side effects have yet to be 
determined. 
 
 
Immunomodulatory agent: Neovir® 
 
Neovir® is an i.m. Immunomodulatory agent, 
composed of sodium oxo – dihydro – acridinyl - 
acetate (ODHAA). 
Normally, it is used to normalise impaired 
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immune system functions under various conditions, 
such as viral infections, immunodeficiency, 
oncological diseases and multiple sclerosis. An 
experimental study evaluated the efficiency of 
acridone acetic acid, sodium salt, in stopping active 
nonsegmental vitiligo progression. Sixty patients with 
active non - segmental vitiligo have been treated with 
ten intramuscular injections, every 48 hours, of 
ODHAA. Vitiligo progression was assessed in 1, 3, 6 
and 12 months after treatment. The results of the 
preliminary study were excellent: sodium 
oxodihydroacridinylacetate showed high efficiency in 
achieving long-term stabilisation of nonsegmental 
vitiligo [20]. 
 
 
Melgain 
  
In the last years, an Indian group of study 
developed a new topical drug (Melgain) for the 
treatment of vitiligo. It is a decapeptide derived from 
bFGF, which has to be applied topically once a day. 
Many data suggest how Melgain is effective in 
inducing repigmentation and particularly safe for 
treating children [21]. 
The combination of Melgain with target 
phototherapy has been demonstrated to be more 
effective. 
 
 
Antioxidants 
 
It is now clear, how oxidative stress of both 
melanocytes and keratinocytes, is an important 
pathogenic mechanism at the base of vitiligo 
progression [22][23]. In particular, the impairment of 
keratinocytes removes the trophic support to 
melanocytes and induces their consequent death. 
Among the mechanisms that have been proposed in 
the prevention of keratinocyte cell stress, SIRT1 
positive modulation has been recently suggested. On 
this observation, recently resveratrol and more 
innovative agents have been proposed and 
successfully tested in vitiligo patients, to protect them 
by the disease’s progression. 
 
 
Low dose medicine (LDM) 
 
Many studies underline how vitiligo is 
characterised by an unbalance of signalling molecules 
(e.g. growth factors, cytokines), that regulate the 
normal cross-talk between keratinocytes and 
melanocytes. In details, vitiligo is characterised by a 
hyper production of Th1 and Th17-related cytokines, 
with an inflammatory action (e.g. TNF - α, INF - γ, IL -
1, IL - 2, IL - 6, IL - 8, IL - 17). Recently, researchers 
and clinicians operating in the field of Low Dose 
Medicine (LDM) had investigated the possibility of 
treatment vitiligo with low dose cytokines, growth 
factors and neuropeptides. In details, it has been 
shown how the use of low oral dose anti-inflammatory 
cytokines (low dose Interleukin - 4 and Interleukin - 
IO; low dose anti-interleukin one antibody) and b - 
FGF, may be useful in restoring the altered 
keratinocytes-melanocytes cross-talk, leading to a 
skin repigmentation. The therapeutic protocol consists 
of the oral intake of 20 drops, twice a day, for 9 
months of Low dose FGF, IL4, IL10 and IL1 [24][25]. 
Different observational studies demonstrated 
the efficacy and the safe profile of LDM in the 
treatment of vitiligo patients. The combination of the 
low dose cytokines with more conventional treatments 
(e.g. topical corticosteroids or micro-focused 
phototherapy) provide better results in term of 
repigmentation rate. 
  
 
Conclusion 
 
Even if asymptomatic and not life threatening, 
vitiligo is a disease psychologically devastating that 
have to be treated. Today different types of therapies 
are available but none of them provide excellent 
results in term of repigmentation rate and safeness. 
For this reason, new studies and experiment have to 
be conducted. 
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